Active, not recruitingPhase 2NCT05621759

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NYU Langone Health
Principal Investigator
Mohammad Maher Abdul Hay
NYU Langone Health
Intervention
Cyclophosphamide(drug)
Enrollment
27 target
Eligibility
18-100 years · All sexes
Timeline
20222027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05621759 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials